NASDAQ:SRNE Sorrento Therapeutics - SRNE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.34 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.32▼$0.3650-Day Range$0.17▼$1.1952-Week Range$0.16▼$3.09Volume1.71 million shsAverage Volume52.69 million shsMarket Capitalization$160.44 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sorrento Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside2,547.1% Upside$9.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.05Upright™ Environmental ScoreNews Sentiment-0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.82) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector753rd out of 1,005 stocksBiological Products, Except Diagnostic Industry129th out of 168 stocks 3.3 Analyst's Opinion Consensus RatingSorrento Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Sorrento Therapeutics has a forecasted upside of 2,547.1% from its current price of $0.34.Amount of Analyst CoverageSorrento Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SRNE. Previous Next 0.0 Dividend Strength Dividend YieldSorrento Therapeutics does not currently pay a dividend.Dividend GrowthSorrento Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSorrento Therapeutics has received a 73.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Glucocorticoids" products. See details.Environmental SustainabilityThe Environmental Impact score for Sorrento Therapeutics is -1.05. Previous Next 0.9 News and Social Media Coverage News SentimentSorrento Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sorrento Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 24 people have searched for SRNE on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 48 people have added Sorrento Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sorrento Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Sorrento Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 34.48% of the stock of Sorrento Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sorrento Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.74) per share.Price to Book Value per Share RatioSorrento Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sorrento Therapeutics (NASDAQ:SRNE) StockSorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.Read More Receive SRNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRNE Stock News HeadlinesMarch 21, 2023 | wsj.comSorrento Therapeutics Opponent Loses Chapter 11 Committee SeatMarch 20, 2023 | americanbankingnews.comSorrento Therapeutics (NASDAQ:SRNE) Research Coverage Started at StockNews.comMarch 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 18, 2023 | wsj.comFirm Retention Summary: Sorrento Therapeutics Inc.March 15, 2023 | thestreet.comWhy Sorrento Therapeutics (SRNE) Stock Plummeted TodayMarch 2, 2023 | finance.yahoo.comIs a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?February 27, 2023 | finance.yahoo.comScilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain managementFebruary 22, 2023 | benzinga.comWhy Sorrento Therapeutics Stock Is Soaring TodayMarch 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.February 22, 2023 | seekingalpha.comSorrento Therapeutics surges 28% as court nods for a $75M loanFebruary 21, 2023 | finance.yahoo.comSorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 CaseFebruary 18, 2023 | finance.yahoo.comSorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)February 17, 2023 | benzinga.comThinking about buying stock in Esports Entertainment, Marathon Digital, Sorrento Therapeutics, Nu Holdings, or ContextLogic?February 15, 2023 | finance.yahoo.comWhy Kim Jong Un’s Daughter Is All Over North Korean MediaFebruary 14, 2023 | finance.yahoo.comSorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerFebruary 14, 2023 | uk.finance.yahoo.comSorrento Therapeutics Files For BankruptcyFebruary 13, 2023 | seekingalpha.comHot Stocks: TDC climbs on earnings; FSLY upgrade; TWLO restructuring; SRNE bankruptcyFebruary 13, 2023 | wsj.comSorrento Therapeutics Files for Bankruptcy to Halt $173 Million Licensing JudgmentsFebruary 13, 2023 | proactiveinvestors.comSorrento Therapeutics stock plummets more than 60% on news of bankruptcy filingFebruary 13, 2023 | markets.businessinsider.comSorrento Therapeutics Stock Is Sinking: What's Going On?February 13, 2023 | finance.yahoo.comSorrento Therapeutics Stock Nosedives After Filing Bankruptcy PaperworkFebruary 13, 2023 | finance.yahoo.comJoint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.February 13, 2023 | benzinga.comThinking about buying stock in Sorrento Therapeutics, Bed Bath & Beyond, C3.ai, Expion360, or SoundHound AI?February 13, 2023 | msn.comSorrento sheds 60% after bankruptcy filing (update)February 13, 2023 | finance.yahoo.comA Sorrento Therapeutics, Inc. (NASDAQ:SRNE) insider increased their holdings by 2.0% last yearFebruary 12, 2023 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraineFebruary 3, 2023 | wsj.comSorrento Issues Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRNE Company Calendar Today3/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRNE CUSIPN/A CIK850261 Webwww.sorrentotherapeutics.com Phone(858) 203-4100Fax858-210-3759Employees799Year Founded2006Price Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+3,576.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-428,330,000.00 Net Margins-818.22% Pretax Margin-877.48% Return on Equity-282.82% Return on Assets-57.64% Debt Debt-to-Equity Ratio0.14 Current Ratio0.88 Quick Ratio0.79 Sales & Book Value Annual Sales$60.32 million Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.31Miscellaneous Outstanding Shares471,880,000Free Float459,611,000Market Cap$160.44 million OptionableOptionable Beta1.95 Social Links Key ExecutivesHenry H. JiChairman, President & Chief Executive OfficerShawn SahebiSenior Vice President-Commercial OperationsElizabeth Adkins CzerepakChief Financial Officer & Executive Vice PresidentMike A. RoyalChief Medical OfficerRobert D. AllenSenior Vice President-Research & DevelopmentKey CompetitorsAcumen PharmaceuticalsNASDAQ:ABOSAdaptimmune TherapeuticsNASDAQ:ADAPTenaya TherapeuticsNASDAQ:TNYAC4 TherapeuticsNASDAQ:CCCCInvivydNASDAQ:IVVDView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 43,714 shares on 3/23/2023Ownership: 0.051%B. Riley Financial Inc.Bought 5,216,250 shares on 3/1/2023Ownership: 1.105%Point72 Middle East FZEBought 130,765 shares on 2/16/2023Ownership: 0.028%Morgan StanleySold 76,142 shares on 2/15/2023Ownership: 0.217%Jane Street Group LLCSold 52,800 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SRNE Stock - Frequently Asked Questions Should I buy or sell Sorrento Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRNE shares. View SRNE analyst ratings or view top-rated stocks. What is Sorrento Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 1 year price targets for Sorrento Therapeutics' stock. Their SRNE share price forecasts range from $5.00 to $13.00. On average, they predict the company's share price to reach $9.00 in the next year. This suggests a possible upside of 2,547.1% from the stock's current price. View analysts price targets for SRNE or view top-rated stocks among Wall Street analysts. How have SRNE shares performed in 2023? Sorrento Therapeutics' stock was trading at $0.8860 at the start of the year. Since then, SRNE stock has decreased by 61.6% and is now trading at $0.34. View the best growth stocks for 2023 here. What other stocks do shareholders of Sorrento Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO). What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." Who are Sorrento Therapeutics' major shareholders? Sorrento Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.89%), B. Riley Financial Inc. (1.11%), B. Riley Financial Inc. (1.11%), Charles Schwab Investment Management Inc. (0.74%), Norges Bank (0.66%) and JPMorgan Chase & Co. (0.66%). Insiders that own company stock include Henry Ji and Kim Janda. View institutional ownership trends. How do I buy shares of Sorrento Therapeutics? Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $0.34. How much money does Sorrento Therapeutics make? Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $160.44 million and generates $60.32 million in revenue each year. How many employees does Sorrento Therapeutics have? The company employs 799 workers across the globe. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759. This page (NASDAQ:SRNE) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.